Anthos’ Abelacimab Receives the US FDA’s Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
Shots:
- The US FDA has granted FTD to abelacimab (factor XI inhibitor) for the treatment of thrombosis associated with cancer
- The P-III CAT program comprises (ASTER) study to evaluate the effect of abelacimab vs apixaban & (MAGNOLIA) study of abelacimab vs dalteparin on VTE recurrence and bleeding in ~2700 patients with cancer-associated VTE across 220 sites in 20+ countries
- In a PK/PD study, abelacimab (IV) delivered profound Factor XI suppression within 1hr. after the start of therapy and maintained near maximal inhibition for ~30 days. In the P-II study, the therapy showed an 80% reduction in the rate of venous thromboembolism over enoxaparin as measured 10 days after surgery
Ref: PRNewswire | Image: Anthos Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
